Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter A Jones

Showing results (161-170 of 165) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 165 results.
Blood Neoplasia|June 17, 2026
Bone marrow immunosuppressive states associate with survival after guadecitabine and atezolizumab therapy in HMA-R/R MDSH Josh Jang, Guillermo Urrutia, Andreas Due Ørskov, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2024
Bone marrow microenvironment signatures associate with patient survival after guadecitabine and atezolizumab therapy in HMA-resistant MDSH Josh Jang, Guillermo Urrutia, Andreas Due Orskov, et al.
Cell Genomics|July 25, 2022
DNA methylation dynamics and dysregulation delineated by high-throughput profiling in the mouseWanding Zhou, Toshinori Hinoue, Bret Barnes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2023
A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor TherapyH Josh Jang, Galen Hostetter, Alexander W Macfarlane, et al.
Nature Cancer|November 18, 2021
Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemiaMelissa B Pappalardi, Kathryn Keenan, Mark Cockerill, et al.
Pageof 17

Showing results (161-170 of 165) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 165 results.
Blood Neoplasia|June 17, 2026
Bone marrow immunosuppressive states associate with survival after guadecitabine and atezolizumab therapy in HMA-R/R MDSH Josh Jang, Guillermo Urrutia, Andreas Due Ørskov, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2024
Bone marrow microenvironment signatures associate with patient survival after guadecitabine and atezolizumab therapy in HMA-resistant MDSH Josh Jang, Guillermo Urrutia, Andreas Due Orskov, et al.
Cell Genomics|July 25, 2022
DNA methylation dynamics and dysregulation delineated by high-throughput profiling in the mouseWanding Zhou, Toshinori Hinoue, Bret Barnes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2023
A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor TherapyH Josh Jang, Galen Hostetter, Alexander W Macfarlane, et al.
Nature Cancer|November 18, 2021
Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemiaMelissa B Pappalardi, Kathryn Keenan, Mark Cockerill, et al.
Pageof 17